KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash & Equivalents (2016 - 2025)

Amgen has reported Cash & Equivalents over the past 17 years, most recently at $9.1 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $9.1 billion for Q4 2025, down 23.75% from a year ago — trailing twelve months through Dec 2025 was $9.1 billion (down 23.75% YoY), and the annual figure for FY2025 was $9.1 billion, down 23.75%.
  • Cash & Equivalents for Q4 2025 was $9.1 billion at Amgen, down from $9.4 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for AMGN hit a ceiling of $34.7 billion in Q3 2023 and a floor of $5.2 billion in Q2 2022.
  • Median Cash & Equivalents over the past 5 years was $9.2 billion (2024), compared with a mean of $12.4 billion.
  • Biggest five-year swings in Cash & Equivalents: surged 558.24% in 2023 and later crashed 74.03% in 2024.
  • Amgen's Cash & Equivalents stood at $8.0 billion in 2021, then decreased by 4.51% to $7.6 billion in 2022, then skyrocketed by 43.45% to $10.9 billion in 2023, then grew by 9.4% to $12.0 billion in 2024, then decreased by 23.75% to $9.1 billion in 2025.
  • The last three reported values for Cash & Equivalents were $9.1 billion (Q4 2025), $9.4 billion (Q3 2025), and $8.0 billion (Q2 2025) per Business Quant data.